Background {#Sec1}
==========

Enterococci are an emerging pathogen in hospitalised patients \[[@CR1]\]. These pathogens ubiquitously occur in the hospital environment and show a high tenacity on inanimate surfaces \[[@CR2]--[@CR4]\]. As a result, enterococcal infections emerge with a rising frequency. Additionally, enterococci have the ability of acquiring resistances to multiple antimicrobial agents and the capacity to transfer resistances to other pathogens via mobile genetic elements \[[@CR5]--[@CR7]\]. For this reason the prevalence of vancomycin resistant enterococci (VRE) has increased intensively \[[@CR1]\]. Vancomycin resistance is associated with enhanced mortality, e.g. among patients with enterococcal blood stream infections \[[@CR8]\]. Within hospital settings prevention of VRE transmission is therefore a major objective.

Infection control strategies to control VRE vary, depending on local guidelines. Usually bundle strategies are applied to prevent transmission of VRE between two patients \[[@CR9]\]. These include contact precautions, intensified disinfection strategies, the usage of personal protective equipment and active surveillance \[[@CR10], [@CR11]\]. In this context, screening strategies are controversially discussed \[[@CR12]\]. Both, generalised screening and a risk-adaptive screening, are possible approaches. Regarding the latter, the question arises, which patient groups should be included. Acquisition of VRE in critical ill patients has been associated with prolonged duration of hospital stay, previous hospitalisations, antibiotic treatment, long-term dialysis and immunosuppression \[[@CR13]--[@CR15]\]. Surgical intensive care patients host a variety of these risk factors, although not explicitly mentioned as risk clientele. Whether surgical intensive care patients per se are at a special risk to acquire VRE and should therefore be included in a risk adapted screening upon subsequent admission to a hospital has not yet been investigated. The present work addresses these questions and investigates risk factors making a VRE acquisition more probable.

Methods {#Sec2}
=======

Clinical setting and infection control measures {#Sec3}
-----------------------------------------------

The 1500-bed University Hospital Münster comprises four interdisciplinary SICUs, hosting abdominal-, trauma-, neuro-, vascular- and thoracic-surgery patients. In total, capacity of all ICUs is 43 beds at its maximum distributed over 26 patient rooms.

Routinely, screening for multidrug-resistant organisms includes an admission-screening for methicillin-resistant *Staphylococcus aureus* (MRSA) and multidrug-resistant Gram-negative bacteria according to the national German guidelines is established \[[@CR16], [@CR17]\]. After coincidental detection of VRE in screening swabs and clinical samples of SICU patients, a prospective investigation was initiated, concentrating on VRE acquisition during a stay on a SICU.

Extended hygiene measures in case of VRE detection include contact isolation in a separate room; cohorting of multiple VRE patients is possible. Sanitary facilities are strictly separated and staff is instructed to wear personal protective equipment in case of entering a patient room, consisting of gloves, and gowns. Surface cleaning disinfection was performed once a day.

Detection of risk factors for VRE acquisition {#Sec4}
---------------------------------------------

During the 2-month study period (August -- October 2017), risk factors for VRE acquisition were prospectively recorded during the entire in-patient stay. These risk factors included demographic data (age, gender), the duration of stay on the respective SICU, underlying diseases (haemato-oncological, immunosuppressive diseases \[e.g. autoimmune-disease, malignancies, HIV-infection, immunomodulatory drug treatment\], hepatic insufficiency, liver transplantation, renal insufficiency, long-term dialysis) and medication (systemic glucocorticoid and antibiotic treatment) attributed to VRE acquisition and previous contacts to the healthcare system (admission from a foreign or domestic hospital, admission from an (in-house) ICU) \[[@CR13]--[@CR15], [@CR18]\]. Patients with a pre-existing VRE status were not included in the analysis, in order to detect risk factors of VRE acquisition on the SICU ward.

VRE screening, culture, antibiotic resistances, PCR testing methods {#Sec5}
-------------------------------------------------------------------

VRE screening was performed upon patients' admission on the SICU as well as upon discharge of patients from the SICU in order to detect VRE acquisition during SICU stay. Hospital-acquired VRE was defined as acquisition \> 48 h after hospitalisation on the SICU. All VRE not acquired during SICU stay were defined as pre-existing VRE. Swabs were obtained rectally (5 cm *ab ano*) (Transwab® m40 compliant, mwe, Corsham, Wiltshire, UK) and subsequently streaked onto chromogenic selective agar (VRESelect™, Biorad, Hercules, California, USA). Suspected colonies were confirmed via MALDI-TOF-MS (Bruker Corporation, Bremen, Germany). Susceptibility testing was performed in accordance with the current European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards for clinical breakpoints (version 7.0) using the VITEK® 2 system (BioMérieux, Nürtingen, Germany). Vancomycin resistance was confirmed by the detection of *vanA*, *vanB*, *vanC1* and *vanC2/3* using the GenoType Enterococcus system (Hain Lifescience, Nehren, Germany). Additionally, subsequent whole genome sequence-based typing confirmed presence of *van*-genes in these isolates.

Whole genome sequence-based typing {#Sec6}
----------------------------------

In order to elucidate the clonal relationship of VRE-strains, isolates were compared genetically via whole genome sequencing (WGS) using the Illumina MiSeq platform (Illumina Inc., San Diego, USA) and laboratory procedures as described previously \[[@CR19]\]. Coding regions were compared in a gene-by-gene approach (core genome multilocus sequence typing, cgMLST) using the SeqSphere+ software version 4.1 (Ridom GmbH, Münster, Germany) \[[@CR20]\]. To visualize the clonal relationship a minimum-spanning tree was generated using the same software. Genotypes that differed in ≤3 cgMLST targets were rated as closely related and highly suspected for a hospital-acquired transmission. For backwards compatibility with classical molecular typing, i. e. MLST, the MLST sequence types (ST) were extracted from the WGS data in silico.

Statistical analysis {#Sec7}
--------------------

All data are expressed as absolute numbers or percentage, if not stated otherwise. Independent risk factors were determined in a two-step analysis. First, a univariate analysis was performed, selecting potential risk factors. Chi-Square test was used for categorical and the two-sided student's t-test for comparison of numerical data. Second, a logistic regression was performed to ascertain the independency of risk factors. Statistical significance was declared at *p* ≤ 0.05.

Results {#Sec8}
=======

Screening adherence, acquired VRE, genotypes {#Sec9}
--------------------------------------------

Table [1](#Tab1){ref-type="table"} shows the detailed results of screening data. Of 374 admitted patients, 336 were screened on admission and 268 on discharge respectively, not considering patients with a confirmed VRE status prior to admission or discharge. In total eight hospital-acquired VRE could be detected. Of all pre-existing VRE (on admission), six presented a *vanA*, 14 a *vanB* and one both genotypes. Of all hospital-acquired VRE, one hosted a *vanA* and seven a *vanB* genotype.Table 1Screening data of SICU-admitted patients (*n* = 374) during August to October 2017Screening resultPositiveNegativeTotal*vanA* genotype*vanB* genotype*vanA* and *vanB* genotypePre-existing VRE6 (66.7%)3 (33.3%)0 (0%)/9Screening on admission0 (0%)11 (3.3%)1 (0.3%)324 (96.4%)336Screening on discharge1 (0.4%)7 (2.6%)0 (0%)260 (97.0%)268

Antimicrobial resistance expressions {#Sec10}
------------------------------------

In total, 29 VRE isolates of 26 patients (one patient was readmitted twice and one patient once) were tested for antimicrobial resistance expressions. Table [2](#Tab2){ref-type="table"} gives a detailed overview of tested substances.Table 2Collection dates, *van*-genotypes, MLST sequence types and antimicrobial resistance expression of VRE strains detected in SICU patients. Each row represents a single patientIsolate no.Collection datePositive resultMLST ST*Van* - genotypeAMPSAMAXAMCPRLTPZIPMCIPLEVVANTECQDTGCLNZCN-HLRS-HLR001\
12315/08/2017\
01/09/2017On admission\
Pre-existingST80\
ST80*vanB*\
*vanB*rrrrrrrrrrsssr----021\
119\
14307/07/2017\
31/08/2017\
04/09/2017Pre-existing\
Pre-existing\
Pre-existingST721\
ST721\
ST721*vanA*\
*vanA*\
*vanA*rrrrrrrrrrrsss+--02502/07/2017Pre-existingST117*vanB*rrrrrrrrrrssss----07625/08/2017On admissionST117*vanB*rrrrrrrrrrssss--+08502/08/2017Pre-existingST721*vanA*rrrrrrrrrrrsss++12605/09/2017On admissionST117*vanB*rrrrrrrrrrssss----18912/09/2017On admissionST80*vanB*rrrrrrrrrrssss--+20426/09/2017On dischargeST80*vanB*rrrrrrrrrrssss--+23520/09/2017On admissionST117*vanB*rrrrrrrrrrssss----24827/03/2017Pre-existingST721*vanA*rrrrrrrrrrrsss+--25122/09/2017On admissionNS*vanA + B*rrrrrrrrrrrrss++25622/09/2017On admissionST117*vanB*rrrrrrrrrrssss----28302/10/2017On dischargeST117*vanB*rrrrrrrrrrssss----29105/10/2017On dischargeST80*vanB*rrrrrrrrrrssss----30004/10/2017On dischargeST80*vanA*rrrrrrrrrrrrss--+30225/10/2017On dischargeST117*vanB*rrrrrrrrrrssss----31413/10/2017On dischargeST117*vanB*rrrrrrrrrrssss----33006/10/2017On admissionST117*vanB*rrrrrrrrrrssss--+33504/10/2017Pre-existingST80*vanB*rrrrrrrrrrssss----33809/10/2017On admissionST117*vanB*rrrrrrrrrrssss----34811/10/2017On admissionST117*vanB*rrrrrrrrrrsrss--+35111/10/2017On admissionST117*vanB*rrrrrrrrrrssss----35202/04/2013Pre-existingST117*vanA*rrrrrrrrrrrrss++36122/10/2017On dischargeST117*vanB*rrrrrrrrrrssss----36613/10/2017On admissionST117*vanB*rrrrrrrrrrssss----37230/10/2017On dischargeST117*vanB*rrrrrrrrrrssss----*MLST* Multilocus sequence typing; *AMP* Ampicillin, *SAM* Ampicillin/sulbactam, *AX* Amoxicillin, *AMC* Amoxicillin/clavulanic acid, *PRL* Piperacillin, *TPZ* Piperacillin/tazobactam, *IPM* Imipenem, *CIP* Ciprofloxacin, *LEV* Levofloxacin, *VAN* Vancomycin, *TEC* Teicoplanin, *QD* Quinopristin/dalfopristin, *TGC* Tigecyclin, *LNZ* Linezolid, *CN-HLR* Gentamicin-high level resistance, *S-HLR* Streptomycin-high level resistance; *r* Resistant, *s* Susceptible, + − positive, − - negative, *NS* not sequenced

Whole genome sequence-based typing and VRE transmission {#Sec11}
-------------------------------------------------------

Of all 29 isolates 25 were subjected to whole genome sequencing. In patients with repetitive VRE detections and the same antimicrobial resistance expression, only the first isolate was undertaken the sequencing procedure. One isolate was not sequenced. Analysing the MLST ST of all sequenced isolates, ST117 was most prevalent (64.0%) followed by ST80 (24.0%) and ST721 (11.0%) (see also Table [2](#Tab2){ref-type="table"}). A genetical comparison with the help of the cgMLST scheme, based on 1423 genes present in all isolates, revealed six clusters, comprising two, three, five and six isolates respectively (Fig. [1](#Fig1){ref-type="fig"}). Two of these clusters contain genotypes of pre-existing isolates and isolates detected in both screenings. Six out of eight VRE isolates (204, 283, 291, 314, 361, 372) detected in patients on discharge, who were previously tested negative for VRE on admission, are genetically closely related to isolates detected in other patients, suggesting a transmission of one VRE clone on ward in these cases (see also Fig. [2](#Fig2){ref-type="fig"}). The other two isolates (300, 302) detected on discharge are genetically unrelated to other isolates, which can be attributed to selection of VRE e.g. via antibiotic application in these patients or a false-negative screening result on admission.Fig. 1Minimum spanning tree of VRE isolates illustrating their genotypic relationship. Minimum spanning tree of 25 VRE strains isolated from intensive care unit patients with VRE anamnesis (*yellow*) and detected during screening on admission (*blue*) and on discharge (*red*) during August and October 2017 based on 1423 cgMLST target genes \[[@CR20]\], pairwise ignoring missing values. Genotypes are numbered chronologically in order of patients' admission on ICU. Each dot represents one genotype. Size of dots correlates with the number of identical genotypes. Numbers near to the connecting lines show the number of alleles differing between two genotypes. Whole Genome Sequencing revealed six clusters of VRE, one *vanA*-cluster and five *vanB*-clustersFig. 2Timeline of detected VRE isolates illustrating time overlap. Timeline of 29 VRE strains isolated from intensive care unit patients with VRE anamnesis (*yellow*) and detected during screening on admission (*blue*) and on discharge (*red*) during August and October 2017. Each row represents one patient. Numbers within coloured boxes indicate the surgical intensive care unit the patient was admitted to. Isolates 302, 361 and 372, detected in screening on discharge, were identified after end the of study period, but included, as the patients, strains were isolated from, were admitted during the observation period

Analysis of risk factors in SICU patients {#Sec12}
-----------------------------------------

Risk factors were compared between the group of hospital-acquired VRE-patients and all patients being not VRE-colonised or infected hospital-acquired. Patients with a pre-existing VRE status were not included in the analysis, in order to detect risk factors of VRE acquisition on the SICU ward. Risk factors to have a significant influence on VRE acquisition in this patient clientele were found to be long-term dialysis (*p* = 0.05), the median duration of stay (*p* = 0.01), and an antibiotic treatment with flucloxacillin (duration of treatment for 5.3 days \[*p* = 0.01\]) or piperacillin/tazobactam (duration of treatment for 4.6 days \[*p* = 0.01\]), while an antibiotic treatment per se did not show a significant risk profile. Further results of the risk factor analyses can be found in Table [3](#Tab3){ref-type="table"}. The multivariate analysis found the duration of stay and flucloxacillin treatment to be statistically significant as shown in Table [4](#Tab4){ref-type="table"}.Table 3Characteristics and risk factors of admitted surgical intensive care patients with and without hospital-acquired VRECharacteristicAll admitted patients (n = 374)Patients with acquired VRE (*n* = 8)Patients without acquired/ pre-existing VRE (*n* = 345)*p*-valueDemographic data Median age (years)66 (range: 14--91)71.5 (range: 50--78)65 (range: 14--91)0.43 Male gender254 (67.9%)4 (50.0%)241 (69.9%)0.23Median duration of stay (days)3 (range: 1--45)14 (range: 7--30)3 (range: 1--45)*0.01*Underlying disease/treatment Haemato-oncological disease62 (16.6%)1 (12.5%)58 (16.8%)0.74 Immunosuppressive disease71 (19.0%)1 (12.5%)66 (19.1%)0.63 Hepatic insufficiency17 (4.5%)0 (0%)15 (4.3%)0.55 Liver transplantation8 (2.1%)0 (0%)8 (2.3%)0.66 Renal insufficiency51 (13.6%)2 (25.0%)41 (11.9%)0.26 Long-term dialysis10 (2.7%)1 (12.5%)7 (2.0%)*0.05* Systemic glucocorticoid treatment36 (9.6%)1 (12.5%)32 (9.2%)0.76 Antibiotic treatment218 (58.3%)7 (87.5%)207 (60.0%)0.11  Ampicillin7 (3.2%)0 (0%)4 (1.9%)0.76  Amoxicillin14 (6.4%)0 (0%)13 (6.3%)0.58  Flucloxacillin20 (9.2%)2 (28.6%)15 (7.2%)*0.01*  Piperacillin/tazobactam62 (28.4%)4 (57.1%)55 (26.6%)*0.01*  Cefuroxime130 (59.6%)1 (14.2%)127 (61.4%)0.16  Ceftriaxone7 (3.2%)0 (0%)3 (1.4%)0.79  Meropenem41 (18.8%)2 (28.6%)36 (17.4%)0.19  Clindamycin7 (3.2%)0 (0%)7 (3.4%)0.68  Daptomycin8 (3.7%)0 (0%)5 (2.4%)0.73  Linezolid3 (1.4%)0 (0%)3 (1.4%)0.79  Rifampicin13 (6.0%)0 (0%)10 (4.8%)0.63  Erythromycin7 (3.2%)0 (0%)6 (2.9%)0.71  Vancomycin19 (8.7%)0 (0%)16 (7.7%)0.53  Fosfomycin7 (3.2%)0 (0%)6 (2.9%)0.71  Trimethoprim/Sulfamethoxazole6 (2.8%)0 (0%)6 (2.9%)0.71  Metronidazole8 (3.7%)0 (0%)7 (3.4%)0.68Previous contact to healthcare system Admission from a foreign hospital1 (0.3%)0 (0%)1 (0.3%)0.88 Admission from a domestic hospital188 (50.2%)5 (62.5%)173 (50.0%)0.49 Admission from an intensive care unit90 (24.1%)4 (50.0%)76 (22.0%)0.06Statistical significance was declared at *p* ≤ 0.05 (see italicized entries)Table 4Multivariate analysis: risk factors associated with VRE acquisitionRisk factors (*p* ≤ 0.05)Odds Ratio95% CIDuration of stay0.900.84--0.96Long-term-dialysis0.080.01--1.10Flucloxacillin treatment0.090.01--0.60Piperacillin/tazobactam treatment0.240.05--1.13

Discussion {#Sec13}
==========

Control of VRE is an emerging topic, patients and healthcare workers have to cope with. An important aspect for prevention of transmission is the early recognition of VRE via screening strategies. Here, the question was addressed, whether SICU patients acquire VRE during their stay and which factors put them at special risk for acquisition. VRE acquisition rate (3.0%) on the SICU was lower than the initial prevalence (3.6%) on admission of all patients. Additionally, no hospital-acquired infection but only colonisations occurred. Distribution of detected *van*-genotypes and MLST ST (*vanB*-genotype and ST117 were most prevalent) are thereby in accordance with national results and trends published for German healthcare institutions recently \[[@CR21]\]. In contrast to another retrospective study investigating hospital-acquired VRE, where the acquisition rate was 28.6%, on different wards including surgical and internal ICUs and lacking a generalised VRE screening, acquisition of VRE in our investigation was comparably low \[[@CR22]\]. Further investigations on haemato-oncological patients revealed one third of these patients to develop hospital-acquired VRE \[[@CR18]\]. SICU patients should per se not be considered as a specific risk clientele for VRE acquisition in comparison with these patients.

Nevertheless, since hospital-acquired VRE colonisations occurred in our patients, risk factors supporting a VRE acquisition in this group of patients were assessed. Here, the median duration of stay, long-term dialysis and the antibiotic treatment with flucloxacillin or piperacillin/tazobactam were found to be the predominant risk factors. These data correspond with previously investigated risk factors and certainly cannot be considered independently but presuppose each other \[[@CR23], [@CR24]\], as also verified by the multivariate analysis. Other risk factors that were found to play an important role in VRE acquisition in other patient clientele could not be verified for our SICU patients. Here, the attributed risk of VRE acquisition after cephalosporin treatment needs to be mentioned. Due to perioperative antibiotic prophylaxis standards, especially referring to cardiac surgery patients, approximately 60% of all admitted patients received cefuroxime; however, this did not lead to an increased VRE acquisition rate. This is noteworthy, since cephalosporine use promotes selection of enterococci and thereby VRE due to intrinsic resistance mechanisms. Nevertheless, previous studies could confirm, that cephalosporine use per se during hospitalization does not result in an enhanced VRE carriage \[[@CR14]\]. Interestingly, since the duration of application of flucloxacillin and piperacillin/tazobactam did not vary significantly among the hospital-acquired VRE and the non VRE group, the present results suggest that few antibiotic applications can be sufficient to potentially select VRE. The impact of relatively low numbers of antibiotic administrations on selection of certain pathogens corroborates similar findings for the selection of *Clostridium difficile* \[[@CR25]\].

Previous contacts to VRE confirmed patients are often mentioned as a major risk factor in VRE acquisition \[[@CR26]\]. Considering the present core genome analysis of isolates, transmission of VRE on ward could not explicitly be excluded in some cases. This may be due to the transmission of this pathogen on inanimate surfaces in advance to the final diagnosis of the VRE status. Hence in case of a confirmed VRE status, adequate basic and, if necessary, intensified hygienic measures consisting of bundle strategies including contact precautions, usage of personal protective equipment, appropriate disinfection strategies, screening of contact patients and antibiotic stewardship should be implemented to avoid transmissions as good as possible.

Our study has limitations. First, the study period was relatively short. Additional risk factors might have been revealed in case of a longer study period. Moreover, distribution of detected MLST ST in found VRE could have been different. Second, we evaluated risk factors promoting VRE carriage, e.g. flucloxacillin and piperacillin/tazobactam application, but did not investigate the pathophysiological background. Future (prospective) studies are needed to reveal underlying mechanisms. Nevertheless, our findings are in accordance with results published previously \[[@CR27]\]. Environmental sampling was not performed during the present study, which could have uncovered the role of inanimate surfaces in VRE transmission, especially in cases of clonality of isolates. Another limitation is the problem of screening sensitivity. Here, only one rectal swab was applied on admission and on discharge respectively, which can lead underestimation of VRE prevalence. However, since screening was performed the same way on admission and on discharge, acquisition rate of VRE during SICU stay can still be assessed precisely.

Conclusion {#Sec14}
==========

Compared to patient clienteles previously investigated \[[@CR23], [@CR28]--[@CR30]\], SICU patients per se are not at higher risk of VRE acquisition if hygiene measures are applied as recommended. If a risk adapted screening policy is applied as practised in other national institutions \[[@CR22]\], stay on a SICU should not be considered as a risk factor for screening upon admission to a healthcare facility.

SICU

:   Surgical intensive care unit

VRE

:   Vancomycin resistant enterococci
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